Indonesia Pravastatin to Prevent Preeclampsia Study

Status Recruiting

Clinical Trial Summary

BACKGROUND Preeclampsia is a major cause of maternal and neonatal morbidity worldwide. There is currently no cure for preeclampsia, the only definitive treatment is termination of pregnancy by induction of labour or caesarean section. Statin has been proposed to represent a new approach to improve disease outcome/prevent preeclampsia based on its multilayered activity toward pregnancy protection, including: protection of vascular endothelial cells survival, induce expression of heme oxygenase 1 (HO-1), inhibiting the release of soluble FMS-like tirosine kinase-1 (sFlt-1) and soluble endoglin (sEng), two main culprits in the pathophysiology of preeclampsia.

OBJECTIVE The aim of this study is to observe the effect of pravastatin administration in patients with high risk of preeclampsia in order to reduce maternal and neonatal mortality and morbidity.

METHODS This is a prospective randomized controlled clinical trial. The research will be held in 5 maternal fetal medicine centers in Indonesia (multicenter study). The recruitment will be done by permuted block random sampling methods, with sample size around 280 patients divides into two group. Patients with high risk of preeclampsia will be randomized either to get pravastatin 2 x 20 mg per oral and aspirin 1 x 80 mg (treatment group) or low dose aspirin only (control group). The patient will be followed regularly until delivery to obtain detailed maternal and neonatal outcome.

OUTCOME Primary Outcomes: Maternal preeclampsia, severe preeclampsia, gestational hypertension, indicated preterm delivery less than 37 weeks, indicated preterm delivery less than 34 weeks, maternal complications, length of hospital stay, and any serious adverse event.

Secondary Outcomes: Composite fetal/neonatal mortality and morbidity (stillbirth, neonatal death, respiratory distress syndrome, intracerebral hemorrhage, neonatal sepsis, intra uterine growth restriction [Small for Gestational Age (SGA) < 5th centile], and necrotizing enterocolitis), birthweight, birthweight percentile, level of care (well baby, intermediate, NICU), NICU length of stay, ventilator usage, and length of perinatal hospital stay.

KEYWORDS: pravastatin, preeclampsia, neonatal mortality, neonatal morbidity

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03648970
Study type	Interventional
Source	Universitas Airlangga
Contact	Muhammad Ilham Aldika Akbar, MD, OBGYN
Phone	+6281703270900
Email	dokter_aldi@yahoo.com
Status	Recruiting
Phase	Phase 2
Start date	March 1, 2018
Completion date	December 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03299777` - Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan	N/A
Completed	`NCT03650790` - C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies	N/A
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Not yet recruiting	`NCT03302260` - Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial	N/A
Completed	`NCT02911701` - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features	Phase 4
Completed	`NCT01911494` - Community Level Interventions for Pre-eclampsia	N/A
Terminated	`NCT02025426` - Phenylephrine Versus Ephedrine in Pre-eclampsia	Phase 4
Completed	`NCT01352234` - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia	Phase 4
Active, not recruiting	`NCT02031393` - Establishing First Trimester Markers for the Identification of High Risk Twin	N/A
Terminated	`NCT00141310` - Sildenafil Citrate for the Treatment of Established Pre-Eclampsia	Phase 2
Completed	`NCT00157521` - L-Arginine in Pre-Eclampsia	Phase 3
Completed	`NCT04795154` - Prenatal Yoga as Complementary Therapy of Preeclampsia	N/A
Completed	`NCT00004399` - Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia	N/A
Completed	`NCT00005207` - Renin and Prorenin in Pregnancy	N/A
Recruiting	`NCT04551807` - Natural Versus Programmed Frozen Embryo Transfer (NatPro)	Phase 3
Terminated	`NCT04092829` - Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer	N/A
Recruiting	`NCT06067906` - Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients	N/A
Recruiting	`NCT06317467` - Role of Anti-C1q Autoantibodies in Pregnancy
Completed	`NCT02218931` - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes	N/A
Active, not recruiting	`NCT04484766` - Preeclampsia Associated Vascular Aging

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Indonesia Pravastatin to Prevent Preeclampsia Study — INOVASIA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms